Navigation Links
Scientists shed light on what causes brain cell death in Parkinson's patients
Date:1/7/2011

SAN ANTONIO (Jan. 7, 2011) Just 5 percent of Parkinson's disease cases can be explained by genetic mutation, while the rest have no known cause. But a new discovery by researchers at The University of Texas Health Science Center San Antonio may begin to explain why the vast majority of Parkinson's patients develop the progressive neurodegenerative disease.

This week in the Journal of Neuroscience, the researchers demystified a process that leads to the death of brain cells or neurons in Parkinson's patients. When researchers blocked the process, the neurons survived.

The findings could lead to an effective treatment to slow the progression of Parkinson's disease, rather than simply address symptoms that include tremors, slowed movement, muscle stiffness and impaired balance. Further studies could lead to a diagnostic test that could screen for Parkinson's years before symptoms develop, said Syed Z. Imam, Ph.D., adjunct assistant professor at the UT Health Science Center.

Parkinson's disease, which usually is not diagnosed until age 60 or later, affects an estimated half-million people in the United States.

Dr. Imam joined the U.S. Food and Drug Administration (FDA) after the research was conducted. Co-authors are from the Health Science Center's Barshop Institute for Longevity and Aging Studies; the South Texas Veterans Health Care System; and the Hertie Institute for Clinical Brain Research in Tbingen, Germany.

The mechanism

After analyzing cells and post-mortem brain tissue from animals and humans, researchers noted that oxidative stress a known culprit in neuron death activated a protein called tyrosine kinase c-Abl in the nigra-striatum area of the brain. Neurons in this part of the brain are particularly vulnerable to Parkinson's injury.

Activation of this protein led to changes in another protein called parkin, which is known to be mutated in hereditary Parkinson's. The altered parkin lacked the capacity to break down other proteins, leading to harmful clumps of unprocessed protein in the neuron. The scientists believe this accumulation leads to progressive neuron death, resulting in Parkinson's symptoms that worsen over time.

Implications

"When we blocked tyrosine kinase c-Abl activation, parkin function was preserved and neurons were spared," Dr. Imam said. "We believe these studies provide sound rationale for moving forward with a preclinical trial of tyrosine kinase c-Abl inhibitors, with the goal of developing a potent therapeutic drug for slowing the progression of Parkinson's."

If preclinical trials in animal models of Parkinson's disease yield positive results, the next step would be clinical trials in human patients, Dr. Imam said.

Tyrosine kinase c-Abl inhibitors are approved by the FDA for treating myeloid leukemia and gastrointestinal tumors. This could speed approval of the drug for Parkinson's and its translation from bench research to clinical practice.

"The race is on to understand the mechanism of the 95 percent of Parkinson's cases with no known cause, and our finding certainly is a building block," Dr. Imam said. "We have found a specific signaling mechanism that is only turned on by oxidative stress and is selective only to Parkinson's-affected neurons of the nigra-striatum, which is the area that sends signals for balance to the cerebellum."


'/>"/>

Contact: Will Sansom
sansom@uthscsa.edu
210-567-2579
University of Texas Health Science Center at San Antonio
Source:Eurekalert

Related medicine news :

1. VIB-K.U. Leuven scientists clear the way to alternative anti-angiogenic cancer therapy
2. Damon Runyon Cancer Research Foundation awards prestigious fellowships to 12 top young scientists
3. Scientists Aim for Test That Spots Single Cancer Cell in Blood Sample
4. Scientists Aim for Test That Could Spot Single Cancer Cell in Blood
5. Scientists Spot DNA Linked With Dangerous Heart Rhythms
6. Ion channel responsible for pain identified by UB neuroscientists
7. Scientists decode secrets of a very common virus that can cause cancer
8. Scientists Spot Genetic Areas Key to Embryonic Development
9. UNC scientists discover potential strategy to improve cancer vaccines
10. Scientists Raise Fat-Burning Levels in Mice
11. Scripps Research scientists awarded $2.35 million to study new obesity treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... ... A man who has struggled to quit smoking, a man who has struggled with hair ... solutions to his problems – and he did. Now Nabat, a serial entrepreneur featured as ... breakthrough inventions to the world and better people's lives. His own experience with nicotine addiction ...
(Date:2/8/2016)... ... 08, 2016 , ... Steve Helwig & Associates Insurance & Financial, serving the ... has teamed up with Citizens Opposed to Domestic Abuse in support of its efforts ... all those victimized by the fear of violence in their own homes, donations may ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... announced today that nominations will be accepted February 8, 2016 through May ... , Awards include the Information Security Executive® of the Year, which recognizes ...
(Date:2/8/2016)... ... February 08, 2016 , ... Discover the Rocky Mountain region’s longest running and ... companies. Attendees also get to see the most incredible gardens and home improvement ... , at the Colorado Convention Center - 700 14th St. Denver CO, is an ...
(Date:2/8/2016)... ... February 08, 2016 , ... Joshua ... on how healthcare companies can use newly released government data on populations and ... population and intervene and capture the value they create to succeed in new ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... Company, Inc. (NYSE MKT: AXN) today announced that for the ... the Company achieved revenue of $8,195,839, a 27% improvement on ... 2015. --> --> The ... $2,068,635, or $.03 per share, up 265% from the net ... of fiscal year 2015. Gross margin for the three months ...
(Date:2/8/2016)...  HemaFlo Therapeutics, Inc. announced today that the United States ... 9,119,880 covering the use of NephroFlow to treat acute kidney ... founder, said, "We are pleased to secure our rights to ... , PhD, HemaFlo,s founder, said, "We are pleased to secure ... Dale Peterson , PhD, HemaFlo,s founder, said, "We ...
(Date:2/8/2016)... Calif. , Feb. 8, 2016  Sangamo ... in therapeutic genome editing, announced that the U.S. ... Company,s Investigational New Drug (IND) application for SB-318, ... life-long therapy for Mucopolysaccharidosis Type I (MPS I). ... enables Sangamo to initiate a Phase 1/2 clinical ...
Breaking Medicine Technology: